Seneffe, Belgium, January 30, 2012. The independent rating agency Hoppenstedt has awarded Eckert & Ziegler BEBIG GmbH, a subsidiary of the Belgium company Eckert & Ziegler BEBIG s.a., the Hoppenstedt CreditCheck Top Rating 1 for excellent solvency. This makes Eckert & Ziegler BEBIG GmbH one of the 4.4% of small and medium-sized companies in Germany to have earned this top grade this year. The award ranks the creditworthiness of 4.7 million small and medium-sized companies in Germany on a scale of 1-6. The assessment is carried out each year by Hoppenstedt Kreditinformationen GmbH.

The certification shows that Eckert & Ziegler BEBIG is excellently positioned in respect of its finances and structured business processes. According to preliminary figures, Eckert & Ziegler BEBIG GmbH had an equity of EUR 6.4 million as of December 31, 2011 and a 44% equity ratio.

"This extremely positive rating means that our business partners can plan with certainty, while our customers can feel confident that they have a reliable partner on their side", explained Dr. Edgar Löffler, Managing Director of Eckert & Ziegler BEBIG s.a.

Eckert & Ziegler BEBIG GmbH is the European market leader in the minimally invasive treatment of prostate cancer using small radioactive implants, known as brachytherapy. It is a subsidiary to Eckert & Ziegler BEBIG s.a. (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB), which has been listed on Euronext since April 2007, and employs over 150 people worldwide.